Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 30 days prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent.
Received small molecule targeted therapy such as TKIs within 2 weeks prior to study enrollment
SAFETY RUN-IN: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
RANDOMIZED PHASE II CLINICAL TRIAL: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
Current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1
Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Any chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first dose of mRNA-4157 or pembrolizumab
Radiotherapy, chemotherapy, or targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1.
Has had prior chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to registration, or who has not recovered (i.e., =< grade 1 or baseline) from adverse events (AEs) due to previously administered agents
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events caused by a previously administered agent
Patient has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1
Prior chemotherapy within 3 weeks, targeted small molecule therapy or radiation therapy within 2 weeks prior to enrollment, or who has not recovered (i.e., ?Grade 1 at enrollment) from AEs due to a previously administered agent.
Current use of systemic corticosteroids greater than (>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of MK-3475 or has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent
Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to trial Day 0 as well as current participation or recipient of treatment on a clinical trial within 28 days prior to Day 0;
Chemotherapy, targeted small molecule therapy, radiotherapy, experimental agents, prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents, or biological cancer therapy (including monoclonal antibodies) within 14 days prior to the start of study drug, or not recovered (=< grade 1 or baseline) from adverse events due to a previously administered agent
Prior chemotherapy, targeted therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e. to =< grade 1 or baseline) from an adverse event due to the previously administered therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.
Prior chemotherapy or targeted small molecule therapy of the current sarcoma. In patients with locally recurrent disease, previous systemic chemotherapy of the primary tumor is allowed, as long as treatment was completed prior to study enrollment and patient has recovered (i.e., < grade 1 or at baseline) from any adverse events due to previously administered agents.
No concurrent chemotherapy or targeted small molecule therapy
Has had prior chemotherapy, radiation, hormonal, monoclonal antibody (mAb) or targeted small molecule therapy, within 2 weeks prior to the first study procedure (apheresis); subjects who have not recovered to < grade 3 from an adverse event due to a previously administered agent are not eligible
Had within 2 weeks prior to the first dose of study treatment, received prior chemotherapy, targeted small molecule therapy, or radiation therapy, or who has not recovered from adverse events due to a previously administered agent or major surgery
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from AEs due to a previously administered agent.
Chemotherapy, monoclonal antibody, targeted small molecule therapy, within 4 weeks prior to dose #1 or who has not recovered (i.e., =< grade 1 or at baseline) for adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study)
Patients who have received chemotherapy, small molecule targeted therapy or radiation within the 2 weeks of first dose of study drugs
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current diagnosis of EGC
Prior chemotherapy or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e. to =< grade 1 or baseline) from an adverse event due to the previously administered therapy
Has had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for the currently diagnosed cancer
Subjects must not have received chemotherapy or targeted small molecule therapy within 4 half-lives of the specific agent(s), or radiation therapy within 2 weeks prior to the first dose of study medication, and must have recovered (=< grade 1) from adverse events related to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 and who have not recovered adequately from this treatment (=< grade 2 toxicity at the time of enrollment)
Has had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for their current diagnosis
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy.
Have received targeted small molecule therapy < 14 days prior to C1D1;
Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment or not recovered from adverse events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from AEs due to a previously administered agent.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
Prior therapy including chemotherapy, targeted small molecule therapy or radiation therapy =< 2 weeks prior to registration OR failure to recover (to =< grade 1 or to baseline) from adverse events (AE) attributable to agents received > 4 weeks prior to registration; NOTE: exception for neuropathy =< grade 2, which is allowed
At least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapy
Has had prior chemotherapy, targeted small molecule therapy, abiraterone treatment, enzalutamide treatment, or radiation therapy within 2 weeks prior to first dose of study therapy or who has not recovered (ie, Grade ?1 or at baseline) from AEs due to a previously administered agent
Prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study Day 1 or prior radiation therapy within 4 weeks prior to study Day 1.
Chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks
Has undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years, has received a live vaccine within 30 days of planned start of study therapy, has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1, received a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered from adverse events due to a previously administered agent
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug, or has not recovered from adverse effects due to a previously-administered agent
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent .
Prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drug
Has had prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to the planned first dose of the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from adverse events due to a previously administered agent.
Prior anti-cancer mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study medication or not recovered from adverse events due to a previously administered agent
Prior mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent.
Prior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent or surgery
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from AEs due to a previously administered agent
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events due to a previously administered agent
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks (12 weeks for measurable sites of central nervous system [CNS] disease) prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy, targeted small molecule therapy, or radiation therapy for current diagnosis of sarcoma
Had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or who has not recovered from adverse events due to a previously administered agent or major surgery
Current use of systemic corticosteroids greater than (>) 20 milligrams (mg) prednisone per day (or equivalent); or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1
Treatment with chemotherapy or biological therapy within the previous 3 weeks, radiation or small molecule targeted therapy within the previous 2 weeks.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy including investigational agents within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent.
Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/ administered agent (i.e., ? grade 1 or return to baseline prior to treatment)\r\n* Note: Subjects with ? grade 2 neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/administered agent (i.e., =< grade 1 or return to baseline prior to treatment)\r\n* Note: subjects with =< grade 2 neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
REGISTRATION TO TREATMENT (STEP 1): Patient must not have had prior chemotherapy, targeted small molecule therapy (aside from imatinib, dasatinib, or nilotinib), or radiation therapy within 2 weeks prior to study registration; patients also must have recovered from all adverse events due to a previously administered agent\r\n* Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system [CNS] disease)
REGISTRATION TO TREATMENT (STEP 2): Patient must not have had prior chemotherapy, targeted small molecule therapy (aside from imatinib, dasatinib, or nilotinib), or radiation therapy within 2 weeks prior to study registration; patients also must have recovered from all adverse events due to a previously administered agent\r\n* NOTE: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis; a 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-CNS disease
Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had a prior monoclonal antibody, chemotherapy, or targeted small molecule therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier (alopecia is an exception)\r\n* Note: Subjects with =< grade 2 neuropathy or ototoxicity are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously\r\nadministered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
COHORT 1: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study.\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
COHORT 2: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to cycle 1 day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Receipt of the last dose or treatment of anti-cancer chemotherapy, radiotherapy, surgery, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization =< 2 weeks (4 weeks for any monoclonal antibody (mAb), 6 weeks for nitrosoureas or mitomycin C) prior to first dose of study treatment, or has not recovered (i.e., to =< grade 1 or Baseline) from clinically significant adverse events (AEs) due to these previously administered agents\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with other irreversible toxicity (e.g., hearing loss) or reversible toxicity (e.g. alopecia) that is not reasonably expected to be exacerbated by the investigational product and is not expected to interfere with study participation may be included\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study day 1 (6 weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to previously administered agents; Note: subjects with =< grade 2 peripheral neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Patients are not eligible who have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to registration or who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy other than pre-specified allowed agents, or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy or chemotherapy-induced alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received treatment with chemotherapy, targeted small molecule therapy, or radiation therapy to non-liver sites within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent administered more than 2 weeks earlier\r\n* Subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 or at baseline) from adverse events due to a previously administered agent and meeting the criteria for organ function; patients who receive palliative radiation therapy within 1 week prior to day 1 are allowed; patients on treatment with targeted therapy (like EGFR or ALK TKIs) may start study treatment 5 days from last treatment; NOTE: subjects with =< grade 2 neuropathy or other clinically insignificant adverse events (AEs) as determined by the PI are an exception to this criterion and may qualify for the study following adequate pre-study documentation; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Prior chemotherapy or radiation therapy =< 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if a patient underwent major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., =< Grade 1 or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: subjects with =< grade 2 neuropathy due to chemotherapy are an exception to this criterion and may qualify for the study\r\n*Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented
Participants must not have had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for disease-specific hormone treatments considered standard of care) within 2 weeks prior to study day 1 or have not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had a prior chemotherapy, immunotherapy, biological therapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy, alopecia or hypothyroidism are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy events due to a previously administered agent
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, a minimum of four weeks must have passed and they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study at the discretion of the treating provider\r\n* Note: If subject received major surgery, they must have recovered adequately, in the opinion of the treating provider, from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention as determined by the investigators prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 28 days prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study with principal investigator (PI) approval\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle1/ Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent(s). Note: Patients with ? Grade 2 neuropathy are an exception to this criterion and may qualify for the trial. Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade 2 hematologic toxicities are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade 2 fatigue are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery or radiation, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: anti-estrogen therapy must be stopped prior to study day 1
Had prior chemotherapy, targeted small molecule therapy within 4 weeks, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent \r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: patients who have received > 30 Gy to the thorax must have completed this radiation 6 months prior to enrollment in the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or to baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from surgery prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients receiving hormone manipulation (e.g. tamoxifen, aromatase inhibitors, LHRH agonist, etc.) for reasons other than treatment of metastatic breast cancer may continue this treatment at the discretion of the investigator
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade 2 hypertension managed with medication are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade 2 endocrinopathy (e.g. hypothyroidism or adrenal insufficiency managed with medication) are an exception to this criterion and may qualify for the study
Participants treated with prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to the prior chemotherapy, targeted small molecule therapy, and radiation therapy\r\n* Note: Subjects with =< grade 2 neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have had the surgery > 2 weeks prior to study day 1 and recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); Note: Patients with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study; Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, radiotherapy, biological cancer therapy, targeted small molecule therapy or major surgery within 21 days prior to study day 1 or who has not recovered (i.e., to CTCAE =< grade 1 or at baseline) from adverse events due to previously administered therapy, Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion\r\nand may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be 4 weeks out from major procedures
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy who has not recovered (i.e., =< grade 1 or at baseline level) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, radiation, or targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* Note: Subjects with alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Lesions that have been selected for HDCRT may have been previously radiated provided:\r\n** The tumor site that was previously radiated has progressed.\r\n** A baseline biopsy of the tumor site is obtained following progression and prior to study entry\r\n* Note: Subjects currently receiving androgen deprivation therapy or hormonal therapy are allowed\r\n* Note: Subjects receiving nitrosoureas within 6 weeks prior to study day 1 are excluded
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with ? Grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n- Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be 4 weeks out from major procedures and 2 weeks out from minor procedures
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered small molecule agent; a. Note: subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study; b. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: participants with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and, has to be at least 28 days after the surgery
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; prior radiotherapy to the liver is not allowed\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent \r\n* Note: subjects with grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have had chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day -14 or who have not recovered (to =< grade 1 or baseline) from adverse events due to a previously administered agent are not eligible\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and do qualify for the study\r\n* Note: if subject received major surgery within 4 weeks prior to day -14, they must have recovered adequately from the toxicity and/or complications per principal investigator (PI) discretion
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy or with hematologic toxicity that has recovered to levels above that stated in inclusion criterion are an exception to this criterion and may qualify for the study if all other inclusion/exclusion criteria are met\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention (i.e., =< grade 1 or at baseline) prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current gynecologic malignancy\r\n* Note: subjects who have received treatment for a prior unrelated malignancy must have recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (ie, =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previous treatment\r\n* Note: subjects with permanent =< grade 2 toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism) are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n*** Note: subjects with asymptomatic =< grade 2 laboratory or dermatologic abnormalities are an exception to this criterion and may qualify for the study pending the judgment of the treating radiation oncologist
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 3 weeks prior to administration of the study drug or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; *Note: Subjects with permanent =< grade 2 toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism), are an exception to this criterion and may qualify for the study; *Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; *Note: Subjects with =< grade 2 amylase or lipase elevations abnormalities that have no corresponding clinical manifestations (e.g. manifestation of pancreatitis), are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study treatment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to extracranial sites may be completed at any time prior to initiation of pembrolizumab;\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, or targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention in the opinion of the principal investigator prior to starting therapy
Has had prior chemotherapy within 3 weeks, or targeted small molecule therapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with any grade alopecia are an exception to this criterion and may qualify for the study
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of MK-3475 or has not recovered (i.e., to =< grade 1 or baseline) from adverse events due to a previously administered agent; Note, subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note, if a subject received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for certain disease-specific hormone and other treatments) within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks (6 weeks for nitrosureas or mitomycin C) prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and be at least 28 days from surgery
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to lymphodepletion or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy, alopecia, hypophysitis stable on physiologic dose of steroid equivalent to prednisone < 10 mg/day, hypothyroidism stable on hormone replacement are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Subject has had prior chemotherapy, targeted small molecule therapy, 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade 2 neuropathy are an exception to this criterion
Has had prior chemotherapy, targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; prior radiation does not require a washout period; note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to day 1 drug administration on study or inability to recover (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: If subject had major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Subject has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patient who has had chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the first dose of study drug, or who has not recovered to CTCAE grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters defined in the inclusion criterion above
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy to the lung or brain within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to other sites may be completed at any time prior to initiation of MK-3475\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters
Has had chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent NOTE: Subjects with ? Grade 2 neuropathy or Grade 2 alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed; or
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 or at baseline) from adverse events due to a previously administered agent; Note: If the subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered to =< grade 1 or baseline from adverse events due to the previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first protocol treatment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Patients who have had prior treatments with tyrosine kinase inhibitors (e.g. Tarceva) require only a 72-hour washout period prior to starting protocol treatment
Patients who have had chemotherapy, targeted small molecule therapy, or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and/or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior monoclonal antibody, chemotherapy (including dexamethasone for multiple myeloma [MM] treatment), targeted small molecule therapy, or radiation therapy within 2 weeks prior to transplant admission (or ~4 weeks prior to the first dose of MK-3475); OR has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent more than 2 weeks prior to transplant admission or more than 4 weeks prior to the first dose of MK-3475; NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to transplant admission; NOTE: Toxicity that has not recovered to =< grade 1 is allowed if it meets the requirements per institutional guidelines for high-dose melphalan and autologous transplant
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks (12 weeks for measurable sites of CNS disease) prior to study Day 1 or not recovered from adverse events (improved to grade 1 or less) due to a previously administered agent\r\n* Note: Subjects with neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Patients may continue on ovarian suppression
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\nNote: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or has not recovered (i.e. =< grade 1 or at baseline) from AEs due to a previously administered agent\r\n* Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If participant underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Participants with alopecia are an exception to this criterion
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to receipt of study medication or who has not recovered (i.e., =< grade 1 or at baseline; excludes alopecia and grade 2 neuropathy) from adverse events due to a previously administered agent\r\n* If subject had major surgery, they must have recovered adequately from the toxicity and complications from the intervention prior to starting therapy
Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., >= grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events from previously administered agents. NOTE: Subjects with ? Grade 2 neuropathy are an exception to this criterion and can still be considered for the study.
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with alopecia, =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to radiation therapy or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: prior radiation therapy does not necessary exclude patients; the index lesion may be acceptable for stereotactic radiosurgery (SRS) and this will be determined by radiation oncologist\r\n* Note: if there is more than one symptomatic lesion, patients will be excluded if the lesions can’t be encompassed within one radiation portal\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Had prior chemotherapy, targeted small molecule therapy within 4 weeks, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent - Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study - Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy -\r\n Note: patients who have received > 30 Gy to the thorax must have completed this radiation 6 months prior to enrollment in the study
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Patients who have had chemotherapy or targeted small molecule therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 (except lenvatinib for patients in cohort 2) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: \r\n** Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n** If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to registration, as deemed by treating investigator or site PI
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >= 3 weeks prior to starting study treatment, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >= 3 weeks prior to starting study treatment; they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; patients who previously received RT in any form would not be eligible\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; note: toxicities that specifically define eligibility for this protocol (nephropathy, otopathy, neuropathy, or other as allowed by principal investigator [PI]) are exceptions
